About Immunai Technologies
Immunai Technologies is a company based in United States founded in 2018 by Luis Voloch and Noam Solomon. Immunai Technologies has raised $295 million across 4 funding rounds from investors including ARE, Talos and Icon Ventures. Immunai Technologies has completed 2 acquisitions, including Dropprint Genomics and NEBION. Immunai Technologies offers products and services including Immunai Platform, Target Discovery, Preclinical Evaluation, and Clinical Trial Optimization. Immunai Technologies operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter United States
- Founders Luis Voloch, Noam Solomon
- Stage Unicorn
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website immunai.com
- Social LinkedIn X
- Total Equity Funding$295M (USD)
in 4 rounds
- Latest Funding Round$215M (USD), Series B
Oct 2021
- InvestorsARE
& 11 more
- Investments & AcquisitionsDropprint Genomics
& 1 more
Products & Services of Immunai Technologies
Immunai Technologies offers a comprehensive portfolio of products and services, including Immunai Platform, Target Discovery, Preclinical Evaluation, and Clinical Trial Optimization.
Platform that generates immune data for drug discovery and trial optimization.
Service to identify novel targets linked to diseases using immune insights.
Tool to prioritize drug candidates through immune system analysis.
System to enhance trial strategies with patient and mechanism insights.
Funding Insights of Immunai Technologies
Immunai Technologies has successfully raised a total of $295M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $215 million completed in October 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $295M
- Total Rounds 4
- Last Round Series B — $215M
- First Round $20M
(May 2020)
- Investors Count 12
All 4 funding rounds of Immunai Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2021 | $215M | Series B | $1B | Koch Disruptive Technologies | |
| Feb 2021 | $60M | Series A | – | Schusterman, Dexcel | |
| Jan 2021 | $344,950 | Grant | – | – | |
| May 2020 | $20M | Seed | – | TLV Partners, Viola Group | – |
| Date | Valuation | Stage |
|---|---|---|
| Oct 2021 | $1B | •••••••• |
Last known valuation $1B (Oct 2021). 12 investors in total: 12 institutional.
Investors in Immunai Technologies
Immunai Technologies has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Talos and Icon Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are invested in by the venture capital firm. | 2017 | kochdisruptivetechnologies.com | Wichita, United States | |
Venture capital firm investing in technology, life sciences, and related sectors. | – | 8vc.com | - | |
Sector-agnostic growth stage VC investment company funding companies in the US and Asia | 1992 | iconventures.com | Palo Alto, United States | |
Commercial loans are brokered by Piedmont Capital for investors. | 2002 | piedmont-capital.com | San Francisco, United States | |
Investments are made in early-stage technology companies globally. | – | viola-group.com | Herzliya, Israel | |
VC firm investing in early stage startups in Israel & the US | – | tlv.partners | Tel Aviv, Israel | |
Venture capital is provided to biomedical technology startups. | – | cataliocapital.com | New York, United States | |
Trade management solutions for digital assets are offered. | 2018 | talos.com | New York, United States | |
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States | |
Philanthropic funding is provided for social justice and equity initiatives. | – | schusterman.org | Tulsa, United States |
Investor details for Immunai Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Immunai Technologies
62 people are tracked at Immunai Technologies (19 in leadership, 12 in board & advisors, 31 in team).
| Name | Role | Group |
|---|---|---|
Luis Voloch | Co-Founder | Leadership |
Noam Solomon | Co-Founder & CEO | Leadership |
Evan Zisholtz | VP, Corporate Development | Leadership |
Galit Yahalom | VP Of Operations | Leadership |
Hila Shilon | Chief Of Staff | Leadership |
Ronit Weinstein | VP Of Human Resources | Leadership |
Jad Maamary | Director | Leadership |
Yosef Dicken | Director Of Strategy & Pharma Alliances | Leadership |
Carmit Alima | Executive Assistant To Chief Executive Officer | Leadership |
Danielle Galanaugh | Director, HRBP | Leadership |
Liya Alexandron | Human Resources Director | Leadership |
Efi Perez | Director Of Global Compensation & Benefits, HRIS And HR Operations | Leadership |
Chava Rothenberg | Director Of Global Talent Acquisition | Leadership |
Alon Shaiber | Associate Director, Computational Biology | Leadership |
Stefan Bleuler | Associate VP Data And Engineering | Leadership |
Guy Yachdav | Senior Director Of Software Engineering | Leadership |
Tali Raveh-Sadka | VP Of Computational R&d | Leadership |
Judith Janette | Associate Director, Lab Operations | Leadership |
David Brocks | Director | Leadership |
Caroline Uhler | Scientific Advisor | Board & advisors |
42 more people are available in the full profile.
Complete people profiles for Immunai Technologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Immunai Technologies
Immunai Technologies has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Dropprint Genomics and NEBION.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Software and services for biomarker and target discovery are provided. | nebion.com | Zurich, Switzerland | 2008 | Jul 2021 | •••• | |
Single-cell technology is developed for genomics datasets in drug discovery. | dropprintgen.com | San Francisco, United States | 2019 | Mar 2021 | •••• |
Complete acquisition details for Immunai Technologies
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Immunai Technologies
6 dated milestones of Immunai Technologies across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Immunai Technologies is founded.
- Funding First funding round of $20.0M.
- Acquisition Acquires Dropprint Genomics.
- Acquisition Acquires NEBION.
- Funding Latest funding round, Series B, of $215.0M.
- Milestone Reaches Unicorn status.
Competitors of Immunai Technologies
Immunai Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| chimerix.com | 2002 | Durham, United Kingdom | $95.23M | 72 | Antiviral oral therapeutics are developed for infectious diseases and cancers. | |
| dnanexus.com | 2009 | Mountain View, United States | $472.55M | 143 | Cloud-based genome informatics and data management are provided. |
Detailed competitors of Immunai Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Immunai Technologies
The website of Immunai Technologies (immunai.com) receives about 16.4K visits a month and ranks #2,881,084 among all websites worldwide, #3,859 in Biotechnology and Pharmaceuticals.
- Monthly visits16.4K
▲ 157.6% vs previous month
- Unique visitors2.5K
per month
- Global rank#2,881,084
among all websites
- Category rank#3,859
Health · Biotechnology and Pharmaceuticals
- Bounce rate52%
- Pages per visit2.4
- Average visit1 min 21 sec
- DevicesDesktop 30% · Mobile 70%
Websites whose visitors overlap most with Immunai Technologies. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| pharmatimes.com | 100% | – | #859,223 | View details | |
| fiercebiotech.com | 66% | 858.3K | #81,022 | View details | |
| hitconsultant.net | 33% | 680.7K | #747,525 | View details |
Latest news on Immunai Technologies
Complete news archive for Immunai Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Immunai Technologies
10 companies that operate in the same segment as Immunai Technologies (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Immunai Technologies
Immunai Technologies was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Immunai Technologies is headquartered in United States.
Noam Solomon is the current CEO of Immunai Technologies. They have also founded this company.
Immunai Technologies is a funded company, having raised a total of $295M across 4 funding rounds to date. The company's 1st funding round was a Seed of $20M, raised on May 2020.
Immunai Technologies was founded in 2018 and is based in the United States. Focus is placed on the biotechnology sector, where next-generation immunomodulatory therapeutics are advanced. Operations involve a proprietary engine known as AMICA, an Annotated Multiomic Immune Cell Atlas. Multi-omic single-cell analysis is integrated with machine learning and functional genomics to support drug discovery and development for immune-modulating medicines.
Immunai Technologies's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Immunai Technologies offers Immunai Platform, Target Discovery, Preclinical Evaluation, and Clinical Trial Optimization.
Immunai Technologies has made 2 acquisitions, including Dropprint Genomics, and NEBION.
Immunai Technologies has 12 investors. Key investors include ARE, Talos, Icon Ventures, European Union, and Koch Disruptive Technologies.
The valuation of Immunai Technologies is $1B as of Oct 2021.